TY - JOUR
T1 - Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma
AU - Matsuo, Koji
AU - Hasegawa, Kosei
AU - Yoshino, Kiyoshi
AU - Murakami, Ryusuke
AU - Hisamatsu, Takeshi
AU - Stone, Rebecca L.
AU - Previs, Rebecca A.
AU - Hansen, Jean M.
AU - Ikeda, Yuji
AU - Miyara, Akiko
AU - Hiramatsu, Kosuke
AU - Enomoto, Takayuki
AU - Fujiwara, Keiichi
AU - Matsumura, Noriomi
AU - Konishi, Ikuo
AU - Roman, Lynda D.
AU - Gabra, Hani
AU - Fotopoulou, Christina
AU - Sood, Anil K.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/7/13
Y1 - 2015/7/13
N2 - Background We compared survival outcomes and risk of venous thromboembolism (VTE) among patients with advanced and early-stage ovarian clear cell carcinoma (OCCC) and serous ovarian carcinoma (SOC), as well as potential links with interleukin-6 (IL-6) levels. Methods A multicenter case-control study was conducted in 370 patients with OCCC and 938 with SOC. In a subset of 200 cases, pretreatment plasma IL-6 levels were examined. Findings Patients with advanced OCCC had the highest 2-year cumulative VTE rates (advanced OCCC 43.1%, advanced SOC 16.2%, early-stage OCCC 11.9% and early-stage SOC 6.4%, P < 0.0001) and the highest median levels of IL-6 (advanced OCCC 17.8 pg/mL, advanced SOC 9.0 pg/mL, early-stage OCCC 4.2 pg/mL and early-stage SOC 5.0 pg/mL, P = 0.006). Advanced OCCC (hazard ratio [HR] 3.38, P < 0.0001), thrombocytosis (HR 1.42, P = 0.032) and elevated IL-6 (HR 8.90, P = 0.046) were independent predictors of VTE. In multivariate analysis, patients with advanced OCCC had significantly poorer 5-year progression-free and overall survival rates than those with advanced SOC (P < 0.01), and thrombocytosis was an independent predictor of decreased survival outcomes (P < 0.01). Elevated IL-6 levels led to poorer 2-year progression-free survival rates in patients with OCCC (50% versus 87.5%, HR 4.89, P = 0.016) than in those with SOC (24.9% versus 40.8%, HR 1.40, P = 0.07). Interpretation Advanced OCCC is associated with an increased incidence of VTE and decreased survival outcomes, which has major implications for clinical management of OCCC.
AB - Background We compared survival outcomes and risk of venous thromboembolism (VTE) among patients with advanced and early-stage ovarian clear cell carcinoma (OCCC) and serous ovarian carcinoma (SOC), as well as potential links with interleukin-6 (IL-6) levels. Methods A multicenter case-control study was conducted in 370 patients with OCCC and 938 with SOC. In a subset of 200 cases, pretreatment plasma IL-6 levels were examined. Findings Patients with advanced OCCC had the highest 2-year cumulative VTE rates (advanced OCCC 43.1%, advanced SOC 16.2%, early-stage OCCC 11.9% and early-stage SOC 6.4%, P < 0.0001) and the highest median levels of IL-6 (advanced OCCC 17.8 pg/mL, advanced SOC 9.0 pg/mL, early-stage OCCC 4.2 pg/mL and early-stage SOC 5.0 pg/mL, P = 0.006). Advanced OCCC (hazard ratio [HR] 3.38, P < 0.0001), thrombocytosis (HR 1.42, P = 0.032) and elevated IL-6 (HR 8.90, P = 0.046) were independent predictors of VTE. In multivariate analysis, patients with advanced OCCC had significantly poorer 5-year progression-free and overall survival rates than those with advanced SOC (P < 0.01), and thrombocytosis was an independent predictor of decreased survival outcomes (P < 0.01). Elevated IL-6 levels led to poorer 2-year progression-free survival rates in patients with OCCC (50% versus 87.5%, HR 4.89, P = 0.016) than in those with SOC (24.9% versus 40.8%, HR 1.40, P = 0.07). Interpretation Advanced OCCC is associated with an increased incidence of VTE and decreased survival outcomes, which has major implications for clinical management of OCCC.
KW - Clear cell carcinoma
KW - IL-6
KW - Ovarian cancer
KW - Survival outcome
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84939576164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939576164&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2015.07.012
DO - 10.1016/j.ejca.2015.07.012
M3 - Article
C2 - 26238017
AN - SCOPUS:84939576164
SN - 0959-8049
VL - 51
SP - 1978
EP - 1988
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 14
M1 - 9546
ER -